Active, not recruitingPHASE1, PHASE2NCT03625037
First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma
Studying Aggressive B-cell non-Hodgkin lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Genmab
- Principal Investigator
- Study OfficialGenmab
- Intervention
- Epcoritamab(biological)
- Enrollment
- 666 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2018 – 2029
Study locations (30)
- Arizona Mayo Clinic, Phoenix, Arizona, United States
- University of California at San Francisco, San Francisco, California, United States
- Colorado Blood Cancer Institute, Denver, Colorado, United States
- H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
- University of Iowa Hospital and Clinics, Iowa City, Iowa, United States
- Ochsner Medical Center, New Orleans, Louisiana, United States
- University of Michigan, Ann Arbor, Michigan, United States
- Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
- University of Nebraska Medical Center, Omaha, Nebraska, United States
- Hackensack Meridian Health, Hackensack, New Jersey, United States
- The Cleveland Clinic Foundation, Cleveland, Ohio, United States
- OHSU Knight Cancer Institute, Portland, Oregon, United States
- Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
- Rhode Island Hospital, Providence, Rhode Island, United States
- Medical University of South Carolina, Charleston, South Carolina, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
AbbVie
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03625037 on ClinicalTrials.govOther trials for Aggressive B-cell non-Hodgkin lymphoma
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONNCT07474051Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical TrialsAvenCell Therapeutics, Inc.
- RECRUITINGEARLY PHASE1NCT07344818An Open and Dose-escalation Early Clinical Study of CD19 and CD20 CAR-T Cell Therapy for Relapsed or Refractory Aggressive B-cell LymphomaPeking University People's Hospital
- RECRUITINGPHASE2NCT07097363Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin LymphomaUniversity of Washington
- RECRUITINGPHASE2NCT06649812Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell LymphomaNational Cancer Institute (NCI)
- RECRUITINGPHASE2, PHASE3NCT07168980Chemotherapy With Rituximab for Aggressive B-NHL in Children and AdolescentsChildren's Cancer Group, China
- RECRUITINGPHASE2NCT06996132Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell LymphomaInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT06834373Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell TherapyMayo Clinic
- RECRUITINGPHASE1, PHASE2NCT06536049Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin LymphomaYazeed Sawalha